Back to Stocks

VCEL

Vericel Corp
6 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Vericel Corporation is demonstrating a powerful commercial inflection point, characterized by a 30.1% year-over-year surge in total revenue to $68.4 million.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the headline revenue growth, Vericel's underlying cost structure reveals significant inefficiencies. Selling, general, and administrative (SG&A) expenses surged 17.8% to $49.2 million, nearly erasing the $49.3 million in gross profit generated during the quarter.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every VCEL filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing presents a company at a crossroads between rapid commercial scaling and the struggle for GAAP profitability. The top-line momentum is undeniable, with MACI and Epicel showing strong demand and gross margins remaining healthy at approximately 72%. The shift to positive operating cash flow is a critical milestone that reduces immediate liquidity concerns and provides a buffer for continued R&D and sales force expansion. However, the synthesis of the data suggests that Vericel's path to the bottom line is hampered by a bloated SG&A profile and inconsistent performance from its NexoBrid line. The BARDA agreement provides a necessary financial lifeline and strategic validation, but the company's ability to convert this into sustainable profit depends on the successful operationalization of the Burlington facility and the ability to scale without proportional increases in overhead. The overall impact of the filing is cautiously optimistic, provided the company can stabilize its operating expenses.

Selected Quarter

Core Takeaway

Vericel is successfully growing its top line and generating positive cash flow, but high operating expenses continue to delay full profitability.

Investor Lens

The trade-off is between impressive top-line acceleration and the ability to control the cost of sales and administration.

Watch Next

FDA qualification of the Burlington facility for Epicel manufacturing and BARDA funding milestones.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.40Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 7

Revenue grew 30.1% YoY driven by MACI and Epicel volume growth.

earnings beat
70%
bullishMay 7

Gross profit increased 35.8% as fixed manufacturing costs were absorbed.

margin expansion
60%
bullishMay 7

Secured a strategic 10-year BARDA agreement with up to $196.9 million in funding.

capital raise
80%
bearishMay 7

SG&A expenses rose 17.8%, nearly offsetting the entire gross profit for the quarter.

margin compression
50%
bullishMay 7

Revenue grew 30.1% YoY driven by MACI and Epicel volume growth.

earnings beat
70%
bullishMay 7

Gross profit increased 35.8% as fixed manufacturing costs were absorbed.

margin expansion
60%
bullishMay 7

Secured a strategic 10-year BARDA agreement with up to $196.9 million in funding.

capital raise
80%
bearishMay 7

SG&A expenses rose 17.8%, nearly offsetting the entire gross profit for the quarter.

margin compression
50%
bullishMay 7

Revenue grew 30.1% YoY driven by MACI and Epicel volume growth.

earnings beat
70%
bullishMay 7

Gross profit increased 35.8% as fixed manufacturing costs were absorbed.

margin expansion
60%
bullishMay 7

Secured a strategic 10-year BARDA agreement with up to $196.9 million in funding.

capital raise
80%
bearishMay 7

SG&A expenses rose 17.8%, nearly offsetting the entire gross profit for the quarter.

margin compression
50%
bullishMay 7

Revenue grew 30.1% YoY driven by MACI and Epicel volume growth.

earnings beat
70%
bullishMay 7

Gross profit increased 35.8% as fixed manufacturing costs were absorbed.

margin expansion
60%
bullishMay 7

Secured a strategic 10-year BARDA agreement with up to $196.9 million in funding.

capital raise
80%
bearishMay 7

SG&A expenses rose 17.8%, nearly offsetting the entire gross profit for the quarter.

margin compression
50%
bullishMay 7

Revenue grew 30.1% YoY driven by MACI and Epicel volume growth.

earnings beat
70%
bullishMay 7

Gross profit increased 35.8% as fixed manufacturing costs were absorbed.

margin expansion
60%
bullishMay 7

Secured a strategic 10-year BARDA agreement with up to $196.9 million in funding.

capital raise
80%
bearishMay 7

SG&A expenses rose 17.8%, nearly offsetting the entire gross profit for the quarter.

margin compression
50%
bullishMay 7

Revenue grew 30.1% YoY driven by MACI and Epicel volume growth.

earnings beat
70%
bullishMay 7

Gross profit increased 35.8% as fixed manufacturing costs were absorbed.

margin expansion
60%
bullishMay 7

Secured a strategic 10-year BARDA agreement with up to $196.9 million in funding.

capital raise
80%
bearishMay 7

SG&A expenses rose 17.8%, nearly offsetting the entire gross profit for the quarter.

margin compression
50%

Filing History

10-QMay 7, 2026
Expand Sequence

The Q1 2026 filing presents a company at a crossroads between rapid commercial scaling and the struggle for GAAP profitability. The top-line momentum is undeniable, with MACI and Epicel showing strong demand and gross margins remaining healthy at approximately 72%. The shift to positive operating cash flow is a critical milestone that reduces immediate liquidity concerns and provides a buffer for continued R&D and sales force expansion. However, the synthesis of the data suggests that Vericel's path to the bottom line is hampered by a bloated SG&A profile and inconsistent performance from its NexoBrid line. The BARDA agreement provides a necessary financial lifeline and strategic validation, but the company's ability to convert this into sustainable profit depends on the successful operationalization of the Burlington facility and the ability to scale without proportional increases in overhead. The overall impact of the filing is cautiously optimistic, provided the company can stabilize its operating expenses.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.